Interchangeability of blood-based biomarkers and PET to identify Alzheimer's disease pathology.

ABSTRACT:

Introduction

Establishing interchangeability between blood biomarkers and amyloid-positron emission tomography (PET) could help identify patients who would benefit from novel amyloid-targeting therapies for Alzheimer's disease.

Methods

Adult participants from the Global Alzheimer's Platform Foundation's Bio-Hermes study with clinical diagnosis of mild cognitive impairment/mild dementia and available amyloid-PET evaluations and Aβ42/40-based PrecivityAD^® (by C2N Diagnostics) and/or phosphorylated tau at threonine 217 (p-Tau217 (research use Meso Scale Discovery, Lilly) were included. Interchangeability between plasma-based tests (per pre-established thresholds) and amyloid-PET stratifications was evaluated.

Results

PrecivityAD (N = 537) and p-T

SUBMITTER: Wang J 

PROVIDER: S-EPMC12865316 | biostudies-literature | 2026 Jan-Mar

REPOSITORIES: biostudies-literature